Keen Eye, a company that designs, develops and markets machine learning solutions for the research and biomedical sectors, announces today that it has finalized a €6 million fundraising led by Crédit Mutuel Innovation and with the Quadrivium 1 Seeding Fund, managed by Seventure Partners, its historical partner. This investment was made in line with the company's development plan, bringing the total funding to €7.5 million since inception.

This funding will enable the company to deploy internationally its latest machine learning technologies for laboratories and biomedical research.

These funds will enable the international commercial deployment of Keen Eye’s biomedical image analysis platform, which is part of a growing market, boosted in particular by recent advances made in machine learning. Keen Eye’s flagship technology offers the ability to identify visual cues that are difficult for experts to recognize, which have significant predictive value for qualifying the effects of disease, treatment outcome, or validating biomarker designs.

For Sylvain Berlemont, Founder and CEO of Keen Eye, "We are very happy to have raised these funds from specialist health tech investors. We will be able to commercialize our collaborative platform in Europe and the United States in the best conditions and fully demonstrate its potential in the laboratories".

Karine Lignel, CEO of Crédit Mutuel Innovation comments: "We are very pleased to support Keen Eye, which has breakthrough technology to play a major role in personalized precision medicine. In the future, biomedical imaging will have to solve complex problems by analyzing and interpreting plethoric data volumes for which existing analysis tools are obsolete. Keen Eye must allow a gain of efficiency and sensitivity".

Philippe Tramoy, Investment Director of the Quadrivium 1 Seed Fund at Seventure Partners, states: "We are very pleased to strengthen our stake in Keen Eye, whose highly innovative technology is part of the on-going revolution in digital pathology. The collaborative platform of Kee Eye allows to generate efficient work organizations and new business models, creating value for its users".

Euronext compartment B
  • ISIN: FR0004027068
  • Ticker: LAN
  • Reuters: LAN.PA
  • Bloomberg: LAN:FP
  • Indices: CAC All Shares, CAC Consumer Goods, EnterNext PEA-PME 150
  • Eligible for PEA-PME schemes (implementing decree of 5 March 2014)
Lanson-BCC

Calyptus

Contact us